Portage announces setting of meeting date to approve SalvaRx acquisition

TORONTO, Nov. 21, 2018 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) - Further to its news releases of August 28 and October 9, 2018, Portage Biotech Inc. ("Portage" or the "Company") is pleased to announce that it has set a shareholder's meeting date to approve the Company's proposed acquisition of SalvaRx Limited from SalvaRx Group plc.

The meeting is scheduled for January 8th, 2019 for shareholders of record as of November 23, 2018. Meeting materials will be distributed shortly after the record date in accordance with the Notice-and-Access provisions of National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer.

Trading in the shares of Portage is expected to resume on CSE shortly after the meeting materials have been posted.

Neither CSE nor its Market Regulator (as the term is defined in the policies of CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward looking statements concerning future operations of Portage Biotech Inc. (the "Company"). All forward looking statements concerning the Company's future plans and operations, including management's assessment of the Company's expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company's control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates and projections.

SOURCE Portage Biotech Inc.

    To read more Press Release articles, click here.